| Patent Number |
Title Of Patent |
Date Issued |
| RE37582 |
Cytokine designated LERK-6 |
March 12, 2002 |
| The invention is directed to LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6. |
| RE36755 |
DNA encoding tumor necrosis factor-.alpha. and -.beta. receptors |
June 27, 2000 |
| Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed. |
| RE35450 |
Soluble human interleukin-1 receptors, compositions and method of use |
February 11, 1997 |
| Soluble human Interleukin-1 receptor proteins (shuIL-1Rs) and methods of using shuIL-1Rs to suppress immune or inflamatory responses in a mammal. |
| RE33252 |
Hybridoma antibody which inhibits Interleukin 2 activity |
July 3, 1990 |
| A process for producing anti-IL-2 antibody from hybridoma cells generated by fusing activated, IL-2 immunized, murine lymphocyte cells with neoplastic murine myeloma cells. Fusion is accomplished by mixing the two cell lines together in the presence of a fusing agent. After fusion, the |
| 7625710 |
Methods for determining 2F1-binding compounds |
December 1, 2009 |
| 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation. |
| 7625553 |
Method of treating cancer by administering an epithelum-derived T-cell factor |
December 1, 2009 |
| Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastr |
| 7589175 |
Human OX2 receptors |
September 15, 2009 |
| Isolated receptors, nucleic acids encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors or agonists thereof. |
| 7585949 |
IL-1 zeta splice variant polypeptide |
September 8, 2009 |
| The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented |
| 7572594 |
Screening assays for agonists or antagonists or receptor activator of NF-.kappa.B |
August 11, 2009 |
| The present invention provides methods for screening for a molecule that antagonizes or agonizes RANK activity. One aspect of the invention involves the growth of RANK responsive cells in semi-solid medium, wherein exposure to a RANK antagonist promotes colony formation. Other aspect |
| 7563450 |
UL16 binding protein 4 |
July 21, 2009 |
| ULBP4, a novel member of the ULBP family has been isolated and characterized. ULBP4 is a useful activator of immune effector cells, particularly of NK cells. |
| 7544784 |
Increased recovery of active proteins |
June 9, 2009 |
| The invention provides methods of increasing yields of desired conformation of proteins. In particular embodiments, the invention includes contacting preparations of a recombinant protein with a reduction/oxidation coupling reagent for a time sufficient to increase the relative propo |
| 7528239 |
Receptor that binds trail |
May 5, 2009 |
| A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors |
| 7517962 |
TWEAK receptor |
April 14, 2009 |
| The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogen |
| 7507807 |
TWEAK receptor |
March 24, 2009 |
| The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogen |
| 7495086 |
TWEAK receptor |
February 24, 2009 |
| The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogen |
| 7476722 |
Methods for purifying protein |
January 13, 2009 |
| A method is provided for separating a protein from one or more other proteins using hydroxyapatite chromatography in which the protein does not bind to hydroxyapatite but the other protein(s) does. In some embodiments, a second protein affixed to a solid support has been used previou |
| 7465450 |
Methods and compositions relating to anti-interleukin-4 receptor antibodies |
December 16, 2008 |
| Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that b |
| 7459528 |
Glycoproteins which bind to TNF |
December 2, 2008 |
| Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed. |
| 7452695 |
Methods for increasing polypeptide production |
November 18, 2008 |
| The invention provides methods of increasing the production of polypeptides, optionally recombinant polypeptides, from mammalian cells using xanthine derivatives or hybrid polar compounds and cultures containing the same. Combinations of inducers including a hybrid polar compound and |
| 7446171 |
SIGIRR DNA and polypeptides |
November 4, 2008 |
| DNA encoding SIGIRR polypeptides and methods for using the encoded polypeptides are disclosed. |
| 7432237 |
Methods of treating asthma by administering interleukin-17 receptor |
October 7, 2008 |
| Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. |
| 7427669 |
ULBP antibodies |
September 23, 2008 |
| The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polype |
| 7416877 |
Receptor that causes cell death and recombinant production thereof |
August 26, 2008 |
| Isolated apoptosis inducing receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof. |
| 7411055 |
Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
August 12, 2008 |
| The present disclosure provides attractin/mahogany-like polypeptides and fragments thereof, polynucleotides encoding such polypeptides and fragments, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides or fragments, and |
| 7411050 |
Monoclonal blocking antibody to human RANKL |
August 12, 2008 |
| Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL. |
| 7405270 |
CD40-Ligand lacking native-pattern glycosylation |
July 29, 2008 |
| There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 re |
| 7405058 |
Human TSLP polynucleotides |
July 29, 2008 |
| The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polype |
| 7402655 |
Molecules designated LDCAM |
July 22, 2008 |
| The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides. |
| 7399832 |
Metalloprotease-disintegrin ADAM23 (SVPH3-17) |
July 15, 2008 |
| The invention is directed to purified and isolated novel SVPH3-13 or SVPH3-17 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived f |
| 7396662 |
C-type lectin polypeptides |
July 8, 2008 |
| Provided herein are polypeptide and polynucleotide sequences for a molecule having homology to the C-type lectin family of polypeptides. Also provided are methods of making and using the polypeptide and polynucleotides. |
| 7384765 |
Cell culture performance with betaine |
June 10, 2008 |
| This invention relates generally to the field of cell culture. More particularly, the invention relates to improving viability of recombinant cell cultures and the yields of secreted polypeptides therefrom by the addition of betaine to the tissue culture medium. |
| 7361330 |
Methods of using flt3-ligand in the treatment of fibrosarcoma |
April 22, 2008 |
| Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma. |
| 7338930 |
Methods of treating osteoarthritis using IL-17 receptor proteins in combination with TNF-recepto |
March 4, 2008 |
| Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor of IL-1 and/or TNF. |
| 7329740 |
Flk-1 binding protein |
February 12, 2008 |
| A protein designated flk-1bp binds the vascular endothelial cell surface receptor flk-1. Isolated DNA encoding flk-1bp is provided, along with expression vectors and transformed host cells useful in producing flk-1bp polypeptides. Antibodies that are immunoreactive with flk-1bp are g |
| 7323558 |
Nucleic acids encoding dendritic cell transmembrane serine protease |
January 29, 2008 |
| Isolated Dendritic Cell Transmembrane Serine Proteases (DCTSPs), DNAs encoding such DCTSPs, and pharmaceutical and/or diagnostic compositions made therefrom, are disclosed. The isolated DCTSPs can be used to hydrolyze peptide bonds. The DCTSPs are also useful in screening for inhibit |
| 7317090 |
Antibodies to Interleukin-4 receptors and uses thereof |
January 8, 2008 |
| Methods and comnositions related to antibodies that bind to mammalian Tnterleulcin-4 recentor proteins are disclosed. |
| 7309489 |
Mouse CD40 ligand-specific antibodies and hybridomas |
December 18, 2007 |
| There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 re |
| 7304144 |
Antibodies binding to human TSLP Polypeptides |
December 4, 2007 |
| The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polype |
| 7294331 |
Methods of using flt3-ligand in hematopoietic cell transplantation |
November 13, 2007 |
| Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells |
| 7288633 |
Modified human thymic stromal lymphopoietin |
October 30, 2007 |
| Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described. |
| 7285648 |
IL-1 delta DNA and polypeptides |
October 23, 2007 |
| DNA encoding IL-1 delta polypeptides and methods for using the DNA and encoded polypeptides are disclosed. |
| 7285643 |
Antibodies to novel murine and human kinases |
October 23, 2007 |
| The invention is directed to purified and isolated novel murine and human kinase polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derive |
| 7285634 |
IL-1 receptor accessory protein |
October 23, 2007 |
| DNA encoding IL-1R AcP splice variant polypeptides, the polypeptides and methods for using the encoded polypeptides are disclosed. |
| 7273843 |
Methods of treating allergy by administering interleukin-17 receptor |
September 25, 2007 |
| Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. |
| 7273609 |
Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or |
September 25, 2007 |
| The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF.alpha. inhibitors by administering agen |
| 7270817 |
ACPL antibodies and methods of use thereof |
September 18, 2007 |
| The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polype |
| 7264809 |
Methods of inhibiting platelet activation and recruitment |
September 4, 2007 |
| The present invention provides soluble CD39 polypeptides and compositions, and methods for inhibiting platelet activation and recruitment in a mammal comprising administering a soluble CD39 polypeptide. |
| 7262274 |
Kits containing rank polypeptides |
August 28, 2007 |
| Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof. |
| 7261894 |
Methods of treating inflammatory and/or autoimmune disease |
August 28, 2007 |
| The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, the use of such polypeptides in |
| 7250507 |
Inhibitory Pellino nucleic acids |
July 31, 2007 |
| There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed. |
